MoneyWorks4Me

Lyka Labs informs about disclosure

10 Oct 2023 Evaluate
Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Lyka Labs has informed that, the Company has received the product permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w. The Company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India.

The above information is a part of company’s filings submitted to BSE.

Lyka Labs Share Price

75.00 0.01 (0.01%)
01-Sep-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1930.45
Dr. Reddys Labs. 1171.00
Cipla 1418.00
Lupin 2150.00
Zydus Lifesciences 1164.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: